treatment with grazoprevir/elbasvir in post-kidney transplant patients with hepatitis c virus genotype 4 infection

Background: kidney transplant (kt) recipients have a high rate of hepatitis c virus (hcv) infection, which can impact long-term graft and patient survival rates. although direct-acting antivirals (daas) are effective for treating hcv, there is limited data on their use in post-kt patients with hcv genotype 4 infection. objectives: to evaluate the effectiveness and occurrence of adverse events with grazoprevir/elbasvir combination treatment without ribavirin in post-kt patients with hcv genotype 4 infection. methods: in this case series, nine therapy-naïve adult post-kt patients with hcv genotype 4 infection were recruited. they had stable graft function and received a fixed dose of grazoprevir/elbasvir (50 mg/100 mg) combination without ribavirin daily for 12 weeks. patients co-infected with hepatitis b virus, hiv, or with evidence of decompensated liver disease were excluded from the study. patients were monitored for viral load, laboratory values, and adverse events associated with drug treatment. the response was defined by the sustained virologic response at 12 weeks (svr12) after the end of treatment. results: all nine patients completed the treatment period and achieved svr12 with no treatment failure or relapse. of them, six patients had hcv genotype 4 infection alone, and three had hcv of mixed genotypes 1 and 4. two (22%) patients showed a rapid hcv clearance at four weeks. no adverse events or serious adverse events were reported. the patients’ renal function was stable during and after the treatment with no deterioration of graft function, and no adjustments to the immunosuppressive therapy were required. conclusions: grazoprevir/elbasvir combination without ribavirin is an effective and safe treatment option for post-kt patients with genotype 4 hcv infection